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When solitary pulmonary tumors are observed in patients with a history of 
cancer, differentiation between metastasis and primary lung cancer is 
crucial for appropriate therapy. Assuming that p53 mutations are con- 
served in metastases, mutation analysis of the p53 gene would be a valuable 
tool in differentiating metastases from primary carcinomas of the lung. In 
nine of 267 resected lung tumors, the origin of the lung tumor could not be 
defined histologically. Five patients had a history of colorectal carcinoma, 
one had a history of breast carcinoma, one had a history of soft-tissue 
carcinoma, and one had a history of head and neck carcinoma. One patient 
with a clear cell carcinoma of the lung had been surgically treated for both 
renal and thyroid cancer. Material  from one patient with adenocarcinoma 
of the lung, histologically defined regional ymph nodes, and distant brain 
metastasis served as a control. We extracted eoxyribonucleic a id from the 
snap-frozen tissue of the unclassified lung tumors, from paraffin-embedded 
tissue of the previously removed pr imary cancers, and also from peripheral 
blood of the patients. Exons 2 to 11 of the p53 gene were amplified in 
separated polymerase chain reactions and directly sequenced. In all cases, 
the presence of germline mutations was excluded by analysis of peripheral 
blood deoxyribonucleic a id. The p53 mutation detected in the deoxyribo- 
nucleic acid of the lung tumor of the control patient proved to be conserved 
in the lymph nodes as well as in the brain metastasis. In two cases, the lung 
tumors exhibited a p53 mutation not present in the previously removed 
pr imary tumor and were therefore classified as new primary lung cancers. 
In five cases, the lung tumors proved to be metastases of the first tumor, 
exhibiting the identical p53 mutation. One of these lung tumor samples 
could be identified as a metastasis from the renal cancer, but the 
corresponding thyroid cancer material  was different. For two cases, molec- 
ular analysis remained inconclusive. In one case, no p53 mutation could be 
found in the compared samples; in the other, no deoxyribonucleic acid 
could be extracted. Analysis of p53 mutations allowed exact classification i
tumors for which standard methods failed to distinguish between metasta- 
sis or pr imary tumor. More than two thirds of lung tumors in patients with 
previous gastrointestinal carcinoma were revealed to be metastases, but 
second pr imary lung cancer could also be diagnosed. This diagnosis 
allowed correct surgical and adjuvant treatment of these patients. 
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A denocarcinoma of the lung, colorectal cancer, and breast cancer are high-prevalence malignant 
tumors. Both colorectal cancer and breast cancer 
tend to metastasize to the lung. Histologically, ade- 
nocarcinoma cells from lung tumor biopsy samples 
may represent a primary lung tumor but may also 
originate from adenocarcinoma of the intestine or 
the breast. The incidence of second primary lung 
cancers in patients with a history of such malignan- 
cies is stated in some centers to be about 70%. 1 
Because techniques for operation and adjuvant 
treatment strategies differ for primary lung cancer 
and metastatic disease, a reliable method for differ- 
entiation of metastases from second malignancies i  
important. Adenocarcinomas of the intestine and of 
the lung do not express characteristic surface mark- 
ers that could be used for differentiation. In breast 
cancer, however, positive test results for progester- 
one or estrogen (present in about half of cases 2) are 
valid for diagnosis. 
In most malignancies, the development and clonal 
expansion of a tumor are preceded by acquisition of 
one or more genetic aberrations, which provide 
tumor cells with a growth advantage. Mutations 
within the p53 tumor suppressor gene are the most 
common genetic alterations associated with malig- 
nant tumors)' 4 The gene product, a 53 kd nuclear 
phosphoprotein, seems to be involved in transcrip- 
tion, deoxyribonucleic a ide (DNA) synthesis, DNA 
repair, programmed cell death, and control of an- 
giogenesis factors important for metastases. Thus 
p53 functions as an important checkpoint in carci- 
nogenesis and tumor progression)' 5 One important 
feature of p53 mutations is their high frequency in 
different umor types, irrespective of stage or tumor 
histology (e.g., lung cancer 50% to 70%, colon 
cancer 50%, and breast cancer 20%6). The proba- 
bility of detecting a p53 mutation in one of two 
independent tumors from the same patient is there- 
fore high and indicates the different origins of these 
tumors. Another characteristic of p53 mutations is 
their great variability concerning site and type of 
mutation. Even if both independent tumors exhibit 
p53 mutations, it is unlikely that these mutations will 
be identical (both the same type and site). Taking 
advantage of these unique attributes of p53 muta- 
tions, we concluded that identical mutations de- 
tected in two different umors sites of a patient are 
indicative of the presence of metastatic disease. The 
aim of our study was to show that mutation analysis of 
the p53 gene provides a valuable tool for differentia- 
tion between metastases and second malignancies. 
Patients and methods 
Patients' data are listed in detail in Table I. For nine of 
267 resected lung specimens from patients with solid lung 
tumors who underwent operation at the Department of 
Cardio-Thoracic Surgery of the University of Vienna 
between August 1992 and September 1994, the origin of 
the tumor could not be defined histologically. Lung spec- 
imens were collected and stored in liquid nitrogen after 
informed consent was obtained from the patients. All nine 
patients had a history of carcinoma of other location. The 
lung tumors could not be classified as metastasis from the 
previous cancer or primary lung cancer by histologic 
examination (Table I). 
From nine patients, we were able to retrieve the 
formalin-fixed and paraffin-embedded s ctions of the pri- 
mary tumor, which had previously been inspected by a 
pathologist council. Five paraffin sections 5~m thick were 
used for DNA extraction. The material was removed from 
the slides and boiled for 10 minutes with 70 to 150 /xl 
Chelex 100 (Bio-Rad Laboratories, Life Science Group, 
Hercules, Calif.) in the following formulation: 2 gm 
Chelex 100, 0.01 gm N-lauryl sulfate, 100/xl Nonidet P-40, 
and 100/xl poly0xyethylenesorbitan mo olaurate 20 with 
water to make 10 ml volume. This solution was then 
centrifuged at 12,000 rpm for 10 minutes. A 2/xl portion 
of the supernatant was diluted appropriately (mostly 
1:10), and dilutions were used for polymerase chain 
reaction (PCR). With DNA from the freshly removed 
lung tumors and the paraffin-embedded material and 
peripheral blood DNA of the patients, PCR amplifica- 
tions of exons 2 through 11 of the p53 gene were carried 
out according to previously reported protocols. 7 
Results 
In one control patient with adenocarcinoma of
the lung, histologically defined brain metastasis, and 
regional ymph node metastases, a p53 mutation in 
exon 5,  which proved to be present in the lung 
sample, the lymph node, and the brain metastasis, 
led to the generation of heteroduplex bands visible 
on polyacrylamide gels (Fig. 1). Direct sequencing 
characterized this mutation as a G-T transversion i
codon 157 of exon 5 of the p53 gene. 
From the nine patients with unclear tumor origin, 
we analyzed 19 specimens for p53 mutations (Table 
II). Patient 42, who exhibited a single pulmonary 
nodule consisting of adenocarcinoma cells 2 months 
after resection of receptor-negative breast cancer, 
exhibited the wild-type sequence in the breast spec- 
imen, whereas the lung tumor showed an eight-base 
deletion in exon 4 (Fig. 2). Patient 65 carried a 
mutation in the resected rectum carcinoma, whereas 
the lung tumor showed wild-type sequence in the 
p53 gene. In five cases (38, 3, 311, 234, and 96) the 
primary cancer and the lung sample showed identi- 
cal p53 mutations (Table II). Patient 96, with a 
history of resected renal and thyroid cancer, exhib- 
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Table I. First cancers and lung tumors: histology and operative treatment 
First resected cancer 
Pt. no. Location Histology Onset Operation 
Resected lung tumor 
Histologic ~pe Onset Operation 
42 Breast cancer Receptor negative, Oct. 1992 
invasive ductal, 
NOS, pTlc-2, 
NO, G2 
38 Carcinoma of the pT3, pNO, G2, Feb. 1992 
rectum Dukes B 
3 Carcinoma of the pT3, pN1, G2, April 1991 
rectum Dukes C1 
311 Carcinoma of the pT3, NO, GZ Dec. 1991 
ascending colon Dukes B 
Carcinoma of the pT3, NO, G2, March 1991 
rectum Dukes B 
65 Carcinoma of the pT2, PN1, G2, Feb. 1992 
rectum Dukes C1 
234 Carcinoma of the pT4, pNO, M1 April 1993 
colon (appendix), 
G2 
96 Hypemephroma pT3, NO, G2 Dec. 1981 
Thyroid carcinoma June 1987 
85 Reticulosarcoma July 1984 
8 Cancer of the base Aug. 1991 
of the tongue 
Quadrantectomy and Adenocarcinoma, G3 Dec. 1992 
axillary dissection 
Proctectomy Adenocarcinoma, G2 Jan. 1993 
Proctectomy Adenocarcinoma, G2 Sept. 1992 
Right hemicolectomy ] 
[ Adenocarcinoma, G2 Nov. 1994 
Proctectomy 
.,I 
Proctectomy Adenocarcinoma, G2 March 1993 
Right hemicolectomy Adenocarcinorna, G2 July 1994 
Pneumonectomy 
Wedge resection 
Bilobectomy 
Lobectomy 
Lobectomy 
Lobectomy 
Nephrectomy ] Clear cell carcinoma June 1993 Video-assisted 
Thyroidectomy / wedge resection 
Resection " Undifferentiated blas- June 1993 Pneumonectomy 
toma, G3 
Resection Squamous cell carci- Sept. 1992 Wedge resection 
noma 
ited a lung metastasis from a clear cell carcinoma. 
No mutation could be found in the thyroid cancer, 
but because of identical mutations in the material 
from the renal carcinoma nd the lung tumor, the 
origin of the latter could be determined (Table II). 
In patient 311, who had resection of a rectal cancer 
followed by resection of a separate colon cancer, the 
lung tumor could be identified as a metastasis from 
the rectum on the basis of identical p53 mutations in 
both samples. Analysis in patient 8, with a history of 
head and neck cancer and squamous cell carcinoma 
of the lung, remained inconclusive because no p53 
mutation could be found. 
In one case (85), no DNA could be extracted from 
the 10-year-old paraffin-embedded section. 
Discussion 
Cancers of similar histologic types in different 
organs often share similar histologic and even sim- 
ilar immunohistochemical features. 
For patients with previous head and neck cancer 
and later lung tumors, Chung and associates 8 
showed with p53 analysis that about two thirds of 
the lung tumors represent second primary cancers. 
For the first time, we analyzed solitary adenocarci- 
nomatous lung tumors in patients with a history of 
cancer of the gastrointestinal tract or breast cancer. 
Lacking a tool for exact diagnosis, such tumors are 
often treated as metastases. However, p53 mutation 
analysis may provide an exact molecular genetic 
diagnosis in such cases. In our series, two of seven 
suspected lung metastases proved to be primary 
lung cancers. Incidentally, because of the location of 
the tumors these two patients had been treated with 
pneumonectomy and lobectomy, correct reatments 
for primary cancers. 
The high frequency of p53 mutations in lung 
cancer without distant metastases of all stages, 
including stage I, 9 indicates that p53 mutations in 
lung cancer are present before metastatic progres- 
sion. In breast cancer, the p53 mutation rate is about 
20%. 10 In colorectal cancer, tl the p53 mutation 
appears to occur during progression to malignancy 
at a rate of 50%. 
Patients with a history of colon or breast or head 
and neck cancer s and solitary lung tumors are the 
main candidate groups for p53 analysis. Because of 
the frequency of such constellations, p53 sequencing 
analysis can be of important clinical value. Addition- 
ally, p53 sequencing analysis can be used for deter- 
mination of poorly differentiated tumors, which 
often do not express any markers, and also to 
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Fig. 1. PCR amplification products of exon 5 of the p53 
gene of a control patient are shown. Heteroduplex bands 
(arrow), indicating the presence of a mutation, could be 
found in the lung cancer (CA) sample, the lymph node 
sample, and the brain metastasis, but not in the peripheral 
blood. Heteroduplex generation is based on the formation 
of DNA double strands consisting of one normal and one 
mutated strand, which causes altered migration on the 
polyacrylamide g l. The mutation could be characterized 
as G-T transversion by direct sequencing (not shown). 
determine how many so-called second primary lung 
cancers are actually first primary lung cancers met- 
astatic to the lung. 
In future, such analyses will lead to correct calcu- 
lation of the risk of second primary lung cancer. 
Obviously, the probability of second primary lung 
cancer should be estimated depending on the loca- 
tion of the first malignancy. The frequency seems to 
be higher in cases of a history of head and neck 
cancer s than among our patients with previous 
gastrointestinal or breast cancer. Although the risk 
in our group was less than one third, the possibility 
of second primary lung cancer in such patients 
should be kept in mind. 
G A T C 8 base 
deletion 
Fig. 2. Sequencing results of exon 4 of the p53 gene of 
patient 42 are shown. DNA from breast cancer shows 
normal sequence. Lung tumor exhibits an eight-base 
deletion. Missing bases are indicated on the normal 
sequence. 
Several authors have provided much evidence 
that p53 mutations are the most common genetic 
alterations among all known cancer-related 
genes.4,5 The characterization of p53 mutations 
can therefore be used to identify the tumor cells 
and their assignment to the tumor clone, taking 
advantage of the fact that the tumor-specific 
genetic mutations are conserved in metastases, as 
was demonstrated in several articles for the p53 
gene.S, 12, 13 In tumor cells, the genetic changes 
are responsible for knocking out cell-cycle con- 
trol, which leads to uncontrolled proliferation. 
These mutations are therefore essential for the 
persistence of a tumor, and it is truly improbable 
that they would disappear as a result of DNA 
repair. Because p53 enables DNA repair by ar- 
resting the cell cycle in G1 phase, 4 inactivation by 
mutation should lead to an accumulation of addi- 
tional mutations in the genome of the tumor cell, 
which might coincide with tumor progression. 11
Apparently, however, these additional mutations 
do not occur in the p53 gene itself; we did not 
observe any additional p53 mutations in any dis- 
tant metastases even after a period of 10 years 
(patient 96). 
P53 abnormalities often have been studied by 
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Table II. Genetic diagnosis of lung tumors 
Pt. p53 mutation of p53 mutation Genetic 
no. first resected cancer of lung tumor diagnosis 
42 
38 
3 
311 
65 
234 
96 
85 
8 
None (wild type) 
C-T transition, exon 8, codon 273; 
C-G transversion, exon 4, codon 72 
1 base insertion, exon 5, codon 152 
Carcinoma of the rectum: None ] 
(wild type) l Carcinoma of the colon; C-T transi- tion, exon 8, codon 282 
C-T transition, exon 5, codon 158 
C-T transition, exon 8, codon 282 
Hypernephroma: C-G transversion, ] 
exon 5, codon 158 1 Thyroid carcinoma." None (wild type) 
No DNA isolation possible 
None (wild type) 
8-base deletion, exon 4, codon 82-84 
C-T transition, exon 8, codon 273; 
C-G transversion, exon 4, codon 72 
1 base insertion, exon 5, codon 152 
C-T transition, exon 8, codon 282 
None (wild type) 
C-T transition, exon 8, codon 282 
C-G transversion, exon 5, codon 158 
None (wild type) 
None (wild type) 
Primary lung cancer 
Metastasis 
Metastasis 
Metastasis of the carcinoma of 
the rectum 
Primary lung cancer 
Metastasis 
Metastasis of the 
hypernephroma 
No diagnosis 
No diagnosis 
immunohistochemistry, which takes advantage of the 
fact that some mutations in the p53 gene increase the 
half-life of the p53 protein, which is not detectable 
under normal circumstances. There are several rea- 
sons for accumulation f p53 protein, however, that do 
not always originate from mutations of the p53 gene. 
Additionally, it is well known that some distinct muta- 
tions increase the instability of the protein, i4 More- 
over, p53 overexpression can occur in the absence of 
p53 mutation, as a cellular answer to genetic damage 
somewhere in the genome. 14
As a non-labor intensive method, immunohis- 
tochemistry is a practical tool to screen for p53 
abnormalities. A molecular genetic differentiation 
of tumors, as shown in our work, depends on the 
possibility of discriminating tumors on the basis of 
different ypes and locations of mutations. Only 
sequencing, which is in fact a labor-intensive 
method that is not currently routinely available, 
provides this information. A method such as p53 
sequencing analysis, however, which is valid for 
differentiation between metastases and second 
primary malignancies of the lung, can support 
correct estimation of prognosis and allow appro- 
priate surgical and adjuvant approaches in these 
patients. 
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Discussion 
Dr. Jack A. Roth (Houston, Texas). I thank the authors 
for providing a copy of their manuscript and congratulate 
Dr. Kandioler and colleagues for an interesting presenta- 
tion. I think that this study is well done, and it is certainly 
encouraging to see other thoracic surgical groups making 
important translational research observations in the mo- 
lecular biology of cancer. I think that this may in fact 
represent one of the first potential applications of this 
type of technology to clinical practice. 
The p53 gene is important in the process of carcinogen- 
esis. It has been characterized as the guardian of the 
genome. This is perhaps omewhat excessive, but it does 
point out that if there are mutations or deletions in the 
p53 gene, this prevents the cell from arresting in the 
G0-G1 phase of the cell cycle and repairing its DNA in 
response to damage. This induces genetic instability and 
may contribute to progression of the cell through the 
process of transformation. 
Two years ago, we published a study that showed that 
primary tumors of the lung, esophagus, and head and neck 
had discordant p53 mutations compared with second 
primary tumors that arose in the same patient, whereas 
the same mutation, as Kandioler and colleagues showed 
here, was present in the primary tumor and documented 
metastases. This has important implications for the pro- 
cess of carcinogenesis. It shows that multiple primary 
cancers of the aerodigestive tract can arise in a field that 
is exposed to a carcinogen and that these cancers arise as 
clonally independent events. 
In this study, the technique was used to distinguish 
between unrelated primary cancers that arise at different 
sites and metastases. It is encouraging that the same 
findings were observed as we reported in our study. 
The determination f p53 mutations i now routine in 
many institutions, and I think it should be possible to 
apply these observations clinically. One reservation, of 
course, is that the same genetic change could be 
observed to occur in separate primary tumors. I think 
that this is a highly improbable vent; however, it must 
be kept in mind that there are certain hot spots in the 
p53 gene and such a coincidence is therefore at least a 
theoretic possibility. 
I have two questions. First, six of the eight primary 
tumors had p53 mutations. This appears to be a somewhat 
high incidence, even for the p53 gene. How did you 
exclude PCR artifacts from introducing mutations in the 
DNA that you analyzed? 
Second, in the clinical setting, the diagnosis must often 
be determined before operatione from a fine-needle 
aspirate. Do fine-needle aspirates provide sufficient cells 
for DNA extraction for your analysis? 
Dr. Kandioler. In response to your first question, we do 
PCR analysis in patients with lung cancer, and we rou- 
tinely isolate DNA from the tumor and a second part of 
the tumor. We resect four parts from the tumor during the 
operation and place them in liquid nitrogen. We then 
isolate tumor material, normal material from the patient, 
and peripheral blood as negative controls to exclude 
artifacts. 
In response to your second question, we have already 
done DNA sequencing analysis from bronchoalveolar 
lavage and biopsy material. We do not need a great 
amount of DNA for this analysis. If you have the advan- 
tage of first analyzing the paraffin-embedded sections 
from these patients' previous tumors, you know in most 
cases which exon carries the mutation, and you have only 
to analyze exactly this exon to differentiate these two 
tumors. The amount of DNA you will need for this 
analysis thus decreases further. 
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